Lixudebart Biosimilar – Anti-CLDN1 mAb – Research Grade from ProteoGenix; catalogue PX-TA1954; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Lixudebart Biosimilar is a newly developed monoclonal antibody (mAb) that specifically targets the claudin-1 (CLDN1) protein. This biosimilar is a research-grade version of the original Lixudebart mAb, which has shown promising results in pre-clinical studies for the treatment of various cancers. In this article, we will explore the structure, activity, and potential applications of Lixudebart Biosimilar as an anti-CLDN1 mAb.
Lixudebart Biosimilar is a chimeric mAb, meaning it is composed of both human and mouse-derived components. The variable region of the antibody is derived from a mouse monoclonal antibody, while the constant region is of human origin. This structure allows for high specificity and affinity towards the CLDN1 protein, while also reducing the risk of immune reactions in patients.
The antibody has a Y-shaped structure, with two identical heavy chains and two identical light chains. Each chain is composed of a variable region, responsible for binding to CLDN1, and a constant region, which facilitates effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
CLDN1 is a tight junction protein that is overexpressed in various types of cancer, including breast, lung, and pancreatic cancer. This protein plays a crucial role in tumor growth and metastasis, making it an attractive therapeutic target. Lixudebart Biosimilar specifically binds to CLDN1, inhibiting its function and disrupting the tight junctions between cancer cells.
In addition to its direct inhibitory effect on CLDN1, Lixudebart Biosimilar also activates the immune system to target cancer cells. The constant region of the antibody binds to Fc receptors on immune cells, triggering ADCC and CDC. This leads to the destruction of cancer cells by immune cells, further enhancing the anti-tumor activity of Lixudebart Biosimilar.
Lixudebart Biosimilar has shown promising results in pre-clinical studies for the treatment of various cancers. In a mouse model of breast cancer, treatment with Lixudebart Biosimilar resulted in significant inhibition of tumor growth and metastasis. Similar results were observed in lung and pancreatic cancer models.
Furthermore, Lixudebart Biosimilar has also been investigated in combination with other anti- cancer therapies. In a study of pancreatic cancer, treatment with Lixudebart Biosimilar in combination with chemotherapy resulted in improved tumor regression and prolonged survival compared to either treatment alone.
Aside from its potential as a cancer therapy, Lixudebart Biosimilar has also shown promise in the treatment of inflammatory diseases. CLDN1 has been implicated in the pathogenesis of inflammatory bowel disease (IBD) and psoriasis. In pre-clinical studies, Lixudebart Biosimilar has been shown to reduce inflammation and improve symptoms in animal models of IBD and psoriasis.
Lixudebart Biosimilar is a novel anti-CLDN1 mAb with a chimeric structure and dual mechanism of action. This biosimilar has shown promising results in pre-clinical studies for the treatment of various cancers and inflammatory diseases. Further clinical trials are needed to fully assess the efficacy and safety of this antibody, but it holds great potential as a targeted therapy for multiple diseases.
Keywords: Lixudebart Biosimilar, anti-CLDN1 mAb, monoclonal antibody, therapeutic target, cancer, inflammation
ProteoGenix catalogue number PX-TA1954. For research use only.
Target: Lixudebart Biosimilar – Anti-CLDN1 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Buffer: 0.01M PBS, pH 7.4; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Lixudebart Biosimilar – Anti-CLDN1 mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
